Advertisement
News
Advertisement

Dominion Diagnostics Supports Opioid Risk Management Program for Fourth Consecutive Year

Wed, 06/08/2011 - 3:32am
Bio-Medicine.Org

NORTH KINGSTOWN, R.I., June 8, 2011 /PRNewswire/ -- Leading national medication monitoring company, Dominion Diagnostics, announces its support of Tufts Health Care Institute's (THCI) Program on Opioid Risk Management for a fourth consecutive year.

Dominion's support of THCI's Program on Opioid Risk Management began in 2007 as part of the company's commitment to promoting the safe and effective use of controlled opioid medications commonly prescribed for chronic pain patients.  The Program aims to address the need to provide chronic pain patients with adequate opioid pharmacotherapy that enhances individual patient care while simultaneously reducing the risk of abuse and/or diversion.

"The mission of THCI's Opioid Risk Management Program is paramount to raising the standard of care for chronic pain patients and addressing the rapidly growing epidemic of prescription drug misuse," says Bob Garvey, Dominion's Chief Executive Officer. "It has become essential to engage such a diverse group of stakeholders in the development and implementation of programs that support prescription adherence, improve patient outcomes, and minimize risk through education, innovative clinical support, and evidence-based quality care."

Through a series of summit meetings each year, the THCI Opioid Risk Management Program provides a unique educational forum to encourage discussion among industry thought leaders.  Summit meeting participants, including Dominion's representatives, review scientific and health industry findings relevant to opioid risk management, and discuss recommendations for future initiatives. The THCI Opioid Risk Management Program has distinguished itself nationally as a high value medium for its exchange of ideas, implementation of awareness goals, and resulting collaborations for research and publication.

Dominion will participate in a two-day summit this week that will focus on pharmacotherapy for prescription opioid addiction

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading